ATARA BIOTHERAPEUTICS, INC. Operating Cash Flow
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Operating Cash Flow of -$6.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.34M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.07M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.70M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.79M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$50.94M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$68.72M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$192.98M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$270.43M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$6.41M 10-Q · filed 2026-08-12 | -$12.11M derived: sum of 3 quarters · filed 2026-08-12 | -$21.89M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$3.07M 10-Q · filed 2026-05-12 | -$8.77M derived: sum of 2 quarters · filed 2026-05-12 | -$18.56M derived: sum of 3 quarters · filed 2026-05-12 | -$25.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$15.48M derived: sum of 2 quarters · filed 2026-03-16 | -$22.80M derived: sum of 3 quarters · filed 2026-08-12 | -$50.94M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$9.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$17.11M derived: sum of 2 quarters · filed 2026-08-12 | -$45.24M 10-Q · filed 2025-11-12 | -$69.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$7.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$35.46M 10-Q · filed 2026-08-12 | -$59.93M derived: sum of 3 quarters · filed 2026-08-12 | -$63.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$28.14M 10-Q · filed 2026-05-12 | -$52.61M derived: sum of 2 quarters · filed 2026-05-12 | -$56.60M derived: sum of 3 quarters · filed 2026-05-12 | -$67.24M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$24.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$28.46M derived: sum of 2 quarters · filed 2026-03-16 | -$39.10M derived: sum of 3 quarters · filed 2026-03-16 | -$68.72M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$14.63M derived: sum of 2 quarters · filed 2025-11-12 | -$44.25M 10-Q · filed 2025-11-12 | -$94.65M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$10.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$40.26M 10-Q · filed 2025-08-11 | -$90.66M derived: sum of 3 quarters · filed 2025-08-11 | -$142.01M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$29.61M 10-Q · filed 2025-05-15 | -$80.02M derived: sum of 2 quarters · filed 2025-05-15 | -$131.36M derived: sum of 3 quarters · filed 2025-05-15 | -$184.16M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$50.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$101.75M derived: sum of 2 quarters · filed 2025-03-07 | -$154.55M derived: sum of 3 quarters · filed 2025-03-07 | -$192.98M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$51.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$104.14M derived: sum of 2 quarters · filed 2024-11-12 | -$142.57M 10-Q · filed 2024-11-12 | -$199.45M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$52.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$91.22M 10-Q · filed 2024-08-12 | -$148.10M derived: sum of 3 quarters · filed 2024-08-12 | -$213.16M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$38.43M 10-Q · filed 2024-05-09 | -$95.31M derived: sum of 2 quarters · filed 2024-05-09 | -$160.37M derived: sum of 3 quarters · filed 2024-05-09 | -$224.33M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$56.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$121.94M derived: sum of 2 quarters · filed 2024-03-28 | -$185.90M derived: sum of 3 quarters · filed 2024-03-28 | -$270.43M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$65.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$129.02M derived: sum of 2 quarters · filed 2023-11-01 | -$213.55M 10-Q · filed 2023-11-01 | -$247.82M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$63.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$148.49M 10-Q · filed 2023-08-08 | -$182.76M derived: sum of 3 quarters · filed 2023-08-08 | -$241.74M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$84.53M 10-Q · filed 2023-05-08 | -$118.80M derived: sum of 2 quarters · filed 2023-05-08 | -$177.78M derived: sum of 3 quarters · filed 2023-05-08 | -$239.35M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$34.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | -$93.25M derived: sum of 2 quarters · filed 2023-02-08 | -$154.82M derived: sum of 3 quarters · filed 2023-02-08 | -$220.52M 10-K · filed 2023-02-08 |
| 2021-09-30 | -$58.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$120.56M derived: sum of 2 quarters · filed 2022-11-08 | -$186.25M 10-Q · filed 2022-11-08 | -$190.37M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | -$61.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$127.28M 10-Q · filed 2022-08-08 | -$131.40M derived: sum of 3 quarters · filed 2023-02-08 | -$184.35M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | -$65.70M 10-Q · filed 2022-05-05 | -$69.82M derived: sum of 2 quarters · filed 2023-02-08 | -$122.78M derived: sum of 3 quarters · filed 2023-02-08 | -$179.41M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | -$4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | -$57.08M derived: sum of 2 quarters · filed 2023-02-08 | -$113.72M derived: sum of 3 quarters · filed 2023-02-08 | -$180.76M 10-K · filed 2023-02-08 |
| 2020-09-30 | -$52.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$109.59M derived: sum of 2 quarters · filed 2021-11-04 | -$176.64M 10-Q · filed 2021-11-04 | -$235.33M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$56.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$123.68M 10-Q · filed 2021-08-09 | -$182.37M derived: sum of 3 quarters · filed 2022-02-28 | -$234.52M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$67.04M 10-Q · filed 2021-05-04 | -$125.73M derived: sum of 2 quarters · filed 2022-02-28 | -$177.88M derived: sum of 3 quarters · filed 2022-02-28 | -$232.47M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$58.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$110.84M derived: sum of 2 quarters · filed 2022-02-28 | -$165.43M derived: sum of 3 quarters · filed 2022-02-28 | -$235.63M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$52.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$106.74M derived: sum of 2 quarters · filed 2020-11-09 | -$176.94M 10-Q · filed 2020-11-09 | -$234.35M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$54.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$124.79M 10-Q · filed 2020-08-05 | -$182.21M derived: sum of 3 quarters · filed 2021-03-01 | -$230.31M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$70.20M 10-Q · filed 2020-05-06 | -$127.62M derived: sum of 2 quarters · filed 2021-03-01 | -$175.72M derived: sum of 3 quarters · filed 2021-03-01 | -$215.15M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$57.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$105.52M derived: sum of 2 quarters · filed 2021-03-01 | -$144.95M derived: sum of 3 quarters · filed 2021-03-01 | -$179.77M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$48.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$87.53M derived: sum of 2 quarters · filed 2019-11-07 | -$122.35M 10-Q · filed 2019-11-07 | -$147.29M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$39.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$74.26M 10-Q · filed 2019-08-08 | -$99.19M derived: sum of 3 quarters · filed 2020-02-27 | -$119.42M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$34.82M 10-Q · filed 2019-05-09 | -$59.76M derived: sum of 2 quarters · filed 2020-02-27 | -$79.99M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | -$24.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$45.17M derived: sum of 2 quarters · filed 2020-02-27 | -$87.50M 10-K · filed 2020-02-27 | |
| 2017-09-30 | -$20.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$62.56M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | -$42.34M 10-Q · filed 2018-08-01 | |||
| 2016-12-31 | -$60.02M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |